i like cydy to do trials such as nash and alzheimers that have a hugh upside
with very little chance of butting heads with big pharma competition wise.plus fda
should look upon cydy very favorably if trial results are strong.my interest is peaked re the kind of alzheimer testing would be done to determine whether a patient is a very early stage candidate and that leronlimab could nip it in the bud? imo